NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types Authors: Soo-Ryum Yang, Matteo Repetto, Erin R. Rudzinski, Marilyn M. Li, Angshumoy Roy, Lauren Gutstein, Karen Huang, Jinhua Wu, Julia Glade Bender, Nicoletta Brega, Arthur M. Buchberg, Vadim Bernard-Gauthier, David S. Hong, Alexander Drilon, Theodore W. Laetsch Published: 2026 ABSTRACT PURPOSENTRK gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a target for tumor-agnostic precision medicine. Tropomyosin receptor kinase (TRK) inhibitors are approved by the US Food and Drug Administration for cancers driven by TRK fusions. However, NTRK genes can fuse with many different partner genes, leading to diverse TRK fusion proteins, highlighting the importance of identifying the specific fusion partner with optimal pan-cancer diagnostics. This analysis aims to provide an updated descriptive compendium of NTRK gene fusions.METHODSNTRK gene fusions were identified via literature searches (PubMed), a search of a clinical trials database (larotrectinib), and searches of two genomic databases (Memorial Sloan Kettering and Children's Hospital of Philadelphia).RESULTSIn total, 358 distinct NTRK gene fusion-tumor pairings were identified across 25 tumor types. Primary CNS tumors were observed to harbor 86 distinct NTRK gene fusions, followed by sarcomas (n = 73). Overall, 229 different fusion partners were identified across tumor types (regardless of NTRK gene). Twenty-three fusion partners were found to fuse with >1 NTRK gene across tumor types, while 183 fusion partners were associated with only a single NTRK gene in one tumor type. ETV6::NTRK3 was found in the highest number of different tumor types.CONCLUSIONThis analysis illustrates the diversity of NTRK gene fusion partners across various tumor types and highlights the importance of selecting a pan-tumor fusion-partner agnostic test that can identify both known and novel fusion partners to identify patients who may benefit from treatment with TRK inhibitors. INTRODUCTION The transmembrane tropomyosin receptor kinase (TRK) family is characterized by tyrosine phosphorylation activity after extracellular binding to neurotrophin growth factors, which activates downstream mitogen-activated protein kinase, phosphoinositide 3-kinase, and rat sarcoma viral oncogene homolog intracellular signaling.1,2 The TRK kinases TRKA, TRKB, and TRKC are encoded by the NTRK family of genes composed of NTRK1, NTRK2, and NTRK3, respectively.1 Physiologic signaling of TRKA, TRKB, and TRKC is involved in the development and function of the nervous system, while pathologic TRK activity arising from somatic structural variants to NTRK1/2/3 genes can induce aberrant expression and/or activation of TRK.1 Pathogenic gene fusions involving NTRK genes occur when the 3′ region of a NTRK gene and the 5′ end of an upstream partner gene join through intrachromosomal or interchromosomal rearrangement, resulting in an in-frame fusion protein that retains the catalytic tyrosine kinase domain of the NTRK gene.3 The kinase domain of the NTRK gene fusion is then constitutively activated in a ligand-independent fashion, leading to cell proliferation and tumor growth.3 NTRK gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a pan-cancer target for precision medicine.3 Overall, NTRK gene fusions have been reported in high frequencies (up to 90%) in rare tumors such as infantile fibrosarcoma and secretory breast cancer and at a lower rate (<1%) across more common tumors such as colorectal cancer and non–small cell lung carcinoma (NSCLC).3-6 Three tumor-agnostic targeted therapies have been approved by the US Food and Drug Administration for cancers driven by TRK fusions to date.7-9 Larotrectinib is the first-in-class, highly selective TRK inhibitor indicated in adult and pediatric patients with NTRK fusion–positive solid tumors.7 Entrectinib is a TRK/ROS1/ALK multikinase inhibitor approved for use in adults with ROS1-positive NSCLC and adult and pediatric patients older than 1 month with NTRK fusion–positive solid tumors.8 Repotrectinib is a next-generation TRK/ROS1/ALK multikinase inhibitor indicated in adults with ROS1-positive NSCLC and adult and pediatric patients older than 12 years with NTRK fusion–positive solid tumors.9,10 NTRK genes can fuse with many different partner genes, leading to diverse TRK fusion proteins. Some fusion partners can introduce homodimerization domains and/or localize the fusion protein to specific cellular compartments with subsequent variations in their catalytic activity and protein interactome.11,12 For example, the fusion partners in the ETV6::NTRK3 and LMNA::NTRK1 fusions predominantly direct the TRK protein to the nuclear or perinuclear compartments, respectively; while NTRK fusions with TPM partners predominantly localize to the cell membrane.13 In addition, the ETV6::NTRK3 fusion encodes the helix-loop-helix (HLH) domain of ETV6, which promotes homodimerization, and deletion of the HLH domain abolishes dimerization and transforming activity.14 Over 80 different fusion gene partners across a variety of tumor types have been reported in reviews of the literature.15,16 Several different techniques are available to detect NTRK gene fusions, including DNA-based next-generation sequencing (NGS) and RNA-based NGS.13 Although DNA-based NGS has the advantage of being widely available and of detecting a broad range of genomic alterations, it can miss fusions due to large intronic regions or breakpoints not covered by the panel.13 By contrast, RNA-based NGS directly captures expressed fusion transcripts, offering higher sensitivity for detecting functional fusions; however, this technique can be limited by the labile nature of RNA, which can lead to degradation in tissue samples and requires specialized laboratory handling.13 The objective of this manuscript is to provide an updated descriptive compendium of NTRK gene fusions identified through a systematic literature search and mining of genomic databases, including extraction from unpublished laboratory databases. This thorough list of NTRK gene fusion partners demonstrates the plethora of tumor types they can occur in, as well as any trends that might occur within a specific tumor type. This resource highlights the importance of biomarker testing and may guide health care providers in the interpretation of rare or unknown partner fusions to identify patients who may benefit from targeted therapy. METHODS NTRK Gene Fusions From the Larotrectinib Clinical Trials Using patient-level data obtained from three larotrectinib clinical trials (ClinicalTrials.gov identifiers: NCT02122913, NCT02637687 [SCOUT], and NCT02576431 [NAVIGATE]), a list of NTRK gene fusions and the associated tumor types in which each fusion was found (fusion-tumor pairings) was collated. The larotrectinib clinical trials integrated data set was used, given the availability of the data. The entrectinib integrated data set publications did not report fusion-tumor pairings; the respective tumor type in which each NTRK gene fusion was identified was not provided.17 Literature Search Strategy: PubMed We performed a systematic literature search in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines18 (Fig 1). On August 1, 2023, a literature search was conducted using the search string in Figure 1 to identify publications on NTRK gene profiling or NTRK gene fusions since October 1, 2019. The start of the date range was selected based on the publication date of an Annals of Oncology supplement that reported approximately 80 distinct gene fusion partners identified at the time of publication.15,19 After removing reviews, titles and abstracts were screened to determine the general type of publication, with the following categories excluded: preclinical, nontumor/noncancer, immunohistochemistry (IHC) only, consensus/commentary, clinical studies involving the larotrectinib clinical trial integrated data set (data cutoff of July 20, 202320), health economics and outcomes research, and corrections/withdrawals. The text and supplementary materials of the remaining manuscripts were then reviewed for NTRK gene fusions reported together with the tumor type. At this step, manuscripts were excluded for the following reasons: no NTRK gene fusions reported/found, partner gene not reported, and NTRK gene fusion-tumor pairing not reported together. No further analyses of excluded papers were performed. PRISMA flow diagram of literature search results. aThe publication was excluded if the NTRK gene fusion-tumor type pairing was previously reported in the larotrectinib clinical trial integrated data set (cutoff July 20, 2023) or if it was reported in the larotrectinib integrated data set but found in a different tumor type. HEOR, health economics and outcomes research; IHC, immunohistochemistry. The remaining records that reported NTRK gene fusion-tumor pairings were then crosschecked against the list of gene fusions and associated tumor types represented in the larotrectinib clinical trial integrated data set. If the tumor type plus NTRK gene fusion pairing reported was already represented in the larotrectinib clinical trial data set, the reference was excluded, and no further analyses were performed. Remaining references were mined for patient-level data, if available. Information of interest included histology, testing method(s) used to identify the NTRK gene fusion, genomic breakpoint locations, and response to TRK inhibition therapy; these were reported descriptively. As this was not a quantitative analysis, no patient-level data were recorded for any NTRK gene fusion-tumor pairings already represented in the larotrectinib clinical trial data set. Genomic Database Search Strategy Two genomic databases were mined for data on patients with tumors harboring NTRK gene fusions. The Memorial Sloan Kettering (MSK) database comprises patients whose tumors have undergone NGS using the MSK-Fusion assay that covers NTRK1, NTRK2, and NTRK3. MSK-Fusion is a targeted RNA-based NGS assay that uses anchored multiplex polymerase chain reaction (via the Archer platform).21 Clinical and molecular data were extracted from the internal cBioPortal for Cancer Genomics platform for MSK investigators after institutional review board approval. The search was conducted on February 1, 2024, for oncogenic NTRK fusions from January 1, 2017, to January 1, 2024, using the following parameters for oncogenic NTRK fusions: (1) non-NTRK gene as the 5′ or upstream fusion partner, (2) NTRK as the 3′ or downstream fusion partner, and (3) fusion containing the NTRK tyrosine kinase domain. The Children's Hospital of Philadelphia (CHOP) database is composed of patients whose tumors have undergone NGS using the CHOP Cancer Fusion Panel,22 which utilizes RNA-based NGS that detects fusion partners included in the panel. The term “NTRK” was used to query the fusion database maintained by the Division of Genomic Diagnostics at the CHOP. The search was conducted on May 24, 2024, and incorporated patients tested between May 2016 and April 2024. The results from the two database searches were categorized into overall tumor types to align with the tumor categories used in the literature search. Patients with nonsolid tumors were excluded. Descriptive Analyses of Search Results Descriptive results for both the PubMed and the genomic databases search results included the number of different NTRK gene fusions by tumor type, the number of different fusion partners found fused to a given NTRK gene, and the number of NTRK genes fused to a given fusion partner. For the PubMed literature results, information regarding treatment with a TRK inhibitor was collected where available (type of inhibitor and response). Breakpoint data reporting the exons defining the fusion junction provided by the database searches were analyzed and described. The list of NTRK gene fusion-tumor pairings identified from the PubMed and database searches were combined with the list of distinct NTRK gene fusions/tumor types represented in the larotrectinib clinical trials to create a comprehensive list of NTRK gene fusions identified in solid tumors via the three sources to qualitatively assess the distribution of NTRK1/2/3 gene fusions across all tumor types. RESULTS Description of Data Sources In the integrated data set of patients pooled from three larotrectinib clinical trials (ClinicalTrials.gov identifiers: NCT02122913, NCT02637687 [SCOUT], and NCT02576431 [NAVIGATE]), 359 adult and pediatric patients treated with larotrectinib were enrolled at the data cutoff of July 20, 2023.20,23 In this data set, there were 147 distinct NTRK gene fusions found across 24 tumor type categories (appendix, bone sarcoma, breast, cancer of unknown primary [CUP], CNS, cervix, cholangiocarcinoma, colorectal, duodenal, esophageal, gastric, head and neck [including external auditory canal], hepatic, lung, melanoma, pancreas, prostate, salivary gland, sarcoma, testes, thymus, thyroid, urothelial, and uterus). Overall, 131 manuscripts published between October 1, 2019, and August 1, 2023, were identified as reporting 183 distinct NTRK gene fusion-tumor pairings across 19 tumor type categories (bone sarcoma, breast, CNS, colorectal, CUP, endometrial, gastric, head and neck [including external auditory canal], lung, melanoma, ovarian, pancreas, prostate, salivary gland, sarcoma, skin [nonmelanoma], thymus, thyroid, and urinary) not represented in the larotrectinib clinical trials data set (Fig 1; Data Supplement, Table S1). In the MSK database, there were 112 patients with solid tumors harboring NTRK gene fusions identified across 13 different tumor types (bladder, breast, cholangiocarcinoma, CNS, colorectal, CUP, head and neck, lung, melanoma, pancreas, salivary, sarcoma [including infantile fibrosarcoma], and thyroid). There were 44 distinct NTRK gene fusions in this cohort. In the CHOP genomic database, there were 67 patients identified who had solid tumors harboring NTRK gene fusions across eight different tumor types (CNS, hematologic, thyroid, kidney, salivary, sarcoma, and skin [melanoma and nonmelanoma]). There were 26 distinct NTRK gene fusions in this cohort. Comprehensive Compendium of NTRK Gene Fusion Partners The list of distinct NTRK gene fusions and associated tumor types from the larotrectinib clinical trial data set was combined with the list of NTRK gene fusion-tumor pairings obtained from the literature search and the two genomic databases to demonstrate the heterogeneity of fusion partners observed across NTRK1/2/3 genes as well as that of NTRK genes observed across tumor types (Fig 2; Data Supplement, Figs S1 and S2). Overall, 358 distinct NTRK gene fusion-tumor pairings were identified across 25 tumor types (Data Supplement, Fig S1). Primary CNS tumors were observed to harbor 86 distinct NTRK gene fusions, followed by sarcomas with 73 distinct NTRK gene fusions, and lung cancers with 52. The distribution of fusions across NTRK genes in these tumors was varied; primary CNS tumors had most gene fusions in NTRK2 genes (NTRK1, 16 [19%] fusions; NTRK2, 52 [60%] fusions; and NTRK3, 18 [21%] fusions), while sarcomas had fewer NTRK2 gene fusions and more NTRK1 and NTRK3 fusions (NTRK1, 30 [41%] fusions; NTRK2, 11 [15%] fusions; and NTRK3, 32 [44%] fusions), and lung cancers had primarily NTRK1 fusions (NTRK1, 38 [73%] fusions; NTRK2, 2 [4%] fusions; and NTRK3, 12 [23%] fusions; Data Supplement, Fig S1). Other tumor types that were highly represented in the consolidated list were melanoma (24 fusions), colorectal (23 fusions), thyroid (21 fusions), and breast (19 fusions). Only 1-3 distinct NTRK gene fusions were reported in 12 of 25 of the tumor types. Heatmap of NTRK gene fusions identified in solid tumors from the larotrectinib clinical trials, PubMed, and the MSK and CHOP genomic databases. NTRK gene fusions shown are the most frequently reported and/or of sufficient distance from adjacent fusions for readability. CHOP, Children's Hospital of Philadelphia; MSK, Memorial Sloan Kettering. There were 229 different fusion partners identified across all solid tumor types (regardless of NTRK gene; Fig 3 and Data Supplement, Table S2). There were 93, 79, and 85 unique partner-gene pairs fused to the NTRK1, NTRK2, and NTRK3 genes, respectively, of which 48 (51.6%), 20 (25.6%), and 25 (29.8%), respectively, were intrachromosomal (Fig 3; Data Supplement, Table S2). Twenty-three fusion partners were found to be fused to >1 NTRK gene across tumor types (Fig 3; Data Supplement, Tables S3 and S4). Of these, five fusion partners (EML4, SQSTM1, STRN3, TFG, and TPM4) were observed across NTRK1/2/3 genes (Fig 3; Data Supplement, Table S3). Of the 206 fusion partners that were fused to only one NTRK gene (Fig 3), 183 were found in only one tumor type (Data Supplement, Table S4). Details of the breakpoints and exon junctions of the fusion partners are included, where available, in the Data Supplement (Table S1) for the NTRK gene fusion-tumor pairings obtained from the literature search. Fusion partners by NTRK gene identified in solid tumors from the larotrectinib clinical trials, PubMed, and the MSK and CHOP genomic databases. Fusion partners are listed regardless of tumor type. aIntergenic region. bIntergenic region upstream. CHOP, Children's Hospital of Philadelphia; MSK, Memorial Sloan Kettering. Certain NTRK gene fusions were observed in >1 tumor type (Fig 4; Data Supplement, Tables S4, S5, and S6). ETV6::NTRK3 was found in the highest number of different tumor types (13 tumor types), including breast, colorectal, head and neck, lung, pancreatic, primary CNS, renal, salivary gland, sarcoma (including infantile fibrosarcoma), skin (nonmelanoma and melanoma), thyroid tumors, and CUP. Specifically, the ETV6::NTRK3 gene fusion was identified in different secretory carcinomas, including that of the breast,24 salivary gland,25 head and neck (external auditory canal),26 sinonasal cavity,27 and skin.28 Other NTRK gene fusions occurring across several tumor types included TPM3::NTRK1 (10 tumor types) and LMNA::NTRK1 (eight tumor types; Fig 4; Data Supplement, Table S5). NTRK gene fusions identified in >1 tumor type from the larotrectinib clinical trials, PubMed, and the MSK and CHOP genomic databases. CHOP, Children's Hospital of Philadelphia; CUP, cancer of unknown primary; MSK, Memorial Sloan Kettering. Treatment With a TRK Inhibitor A subset of publications, excluding those of tumor types plus NTRK gene fusion pairings already represented in the larotrectinib clinical trial data set, reported patients who were treated with a TRK inhibitor (Data Supplement, Table S1). Of these 30 publications, larotrectinib was the most common TRK inhibitor reported (20 publications; Data Supplement, Table S7). Responses ranged from complete response to progressive disease, with 100% reduction in tumor size/complete response achieved in three patients with NTRK gene fusion-tumor pairings not represented in the larotrectinib clinical trials (ETV6::NTRK3 in head and neck cancer [secretory carcinoma of the external auditory canal],26 STRN1::NTRK2 in high-grade glioneuronal tumor,29 and TRIM63::NTRK1 in lung adenocarcinoma30; Data Supplement, Table S7). The next most reported TRK inhibitor was entrectinib (10 publications) and response ranged from complete response in one patient with gene fusion-tumor pairing of EML4::NTRK3 in lung cancer to progressive disease (Data Supplement, Table S7). Other inhibitors reported in the literature included crizotinib (one publication), imatinib (one publication), regorafenib (one publication), and repotrectinib (one publication; Data Supplement, Tables S1 and S7). Breakpoint Data From Genomic Database Search Results Across the MSK database of 114 patients with NTRK gene fusion cancer, the most common gene fusion identified was ETV6::NTRK3 (n = 25); the most common tumor types were thyroid (n = 5) and salivary (n = 5, including three secretory carcinoma of the salivary gland). There were three different breakpoints identified across the 25 ETV6::NTRK3 gene fusions found in this cohort (Data Supplement, Table S8). A further 15 patients had tumors harboring a TPM3::NTRK1 gene fusion (including six sarcomas and four colorectal cancers). There were five different breakpoints identified for the TPM3::NTRK1 gene fusions in this cohort (Data Supplement, Table S8). The gene fusion with the highest number of different breakpoints identified was LMNA::NTRK1, with eight breakpoint locations found in 10 patients across five different tumor types (breast, colorectal, melanoma, sarcoma, and skin [nonmelanoma]; Data Supplement, Table S8). Across the CHOP database of 70 patients with NTRK gene fusion cancer, the most common gene fusion identified was ETV6::NTRK3 (n = 28); 16 patients had a diagnosis of thyroid carcinoma. There were three different breakpoints identified across the 28 ETV6::NTRK3 gene fusions found in this cohort (Data Supplement, Table S9). There were three distinct breakpoints observed in the four patients with tumors harboring TPR::NTRK1 (all papillary thyroid carcinomas; Data Supplement, Table S9). DISCUSSION The results of this analysis illustrate the diversity of NTRK gene fusion partners across various tumor types, with identification of 358 distinct NTRK gene fusion-tumor pairings across 25 tumor types. The wide array of tumor types found to harbor an NTRK gene fusion, as well as the fact that a given NTRK gene fusion could be found in >1 tumor type (eg, ETV6::NTRK3, TPM3::NTRK1, and LMNA::NTRK1), underscores the importance of comprehensive, partner-agnostic testing strategies. Some tumor types harbored many distinct NTRK gene fusions, including primary CNS tumors (86 fusions), sarcomas (73 tumors), and lung cancers (52 fusions), while eight of 25 tumor types were associated with only one distinct NTRK gene fusion (skin [nonmelanoma], hepatic, appendiceal, endometrial, ovarian, renal, testicular, and uterine tumors). Certain types of cancers had a greater incidence of involvement with a particular NTRK gene. For example, 60% of primary CNS tumors harbored an NTRK gene fusion involving NTRK2, a finding consistent with prior reviews.31-33 Similarly, 73% of lung cancers harbored NTRK gene fusions involving NTRK1, which also aligned with previous reviews.31,34 The most common NTRK gene fusions across tumor types were ETV6::NTRK3, TPM3::NTRK1, and LMNA::NTRK1 in 13, 10, and 8 tumor types, respectively, all of which were observed in breast, colorectal, CUP, lung, melanoma, and sarcoma tumor types. These data show the importance of pooling NTRK gene fusion data across sources; for example, in the larotrectinib clinical trial database, only one gene fusion (ETV6::NTRK3) has been associated with salivary cancer, but an additional gene fusion (ZCCHC7::NTRK2) has been identified in this pooled analysis that includes genomic databases and literature searches. Growing evidence indicates that different fusion partners can influence the subcellular localization of TRK activation in NTRK gene fusions; this suggests that partner identity may modulate oncogenic signaling and highlights a potential rationale for partner-informed therapeutic strategies.3,11,35 In most cases, the fusion transcript is driven by the promoter of the 5′ partner gene.15 The resulting fusion protein generally includes one or more dimerization domains from the partner gene; these domains contribute to the ligand-independent dimerization and constitutive tyrosine kinase domain activation.1,3,16 Although the presence of an intact tyrosine kinase domain is essential for the fusion to be oncogenic, the transmembrane domain is not present in certain fusion proteins. It is thought that inclusion of the transmembrane domain may affect cellular localization of the fusion protein, varying with the fusion partner.1,3 There are several testing methods available to detect the presence of an NTRK gene fusion, including DNA-based NGS and RNA-based NGS.1,13 Beyond logistical factors such as testing cost, availability, and turnaround time, knowledge of the specific characteristics of NTRK gene fusions within particular tumor types should also be leveraged when selecting the testing method.1 As previously described, cellular localization of the fusion protein may vary with the fusion partner, thereby having implications for the pattern of IHC staining seen.1,36,37 Although pan-TRK IHC has demonstrated sensitivities of 96.2% and 100% for NTRK1 and NTRK2 gene fusions, respectively, sensitivity for NTRK3 gene fusions is lower at 79.4%.36 Sensitivity and specificity of pan-TRK IHC also depends upon the tumor type, being lower for breast cancers and salivary gland tumors (due to cytoplasmic staining), as well as CNS tumors and sarcomas (due to the normal expression of TRK proteins in neural and smooth muscle tissue)36; therefore, other testing methods should be used in these tumor types. Furthermore, the sensitivity of IHC may vary across laboratories because there is no standard validated companion diagnostic IHC assay. Although break-apart fluorescence in situ hybridization has been historically used for detecting gene rearrangements, it does not identify the fusion partner and cannot confirm the presence of the tyrosine kinase domain, limiting its diagnostic utility. More recently, DNA-based NGS has been increasingly used for fusion detection.15 Although NTRK fusions can be detected if the intronic regions spanning the breakpoints are sufficiently covered, the large size of NTRK2, and especially NTRK3, decrease the sensitivity of DNA-based NGS.16,36 Also, the repetitive regions of the intronic regions of NTRK3 fusions are difficult to tile.13 In other cases, DNA-based NGS may reveal atypical NTRK rearrangements of unknown significance (eg, fusions lacking the tyrosine kinase domain or NTRK as the upstream partner), which limits specificity and would require an orthogonal assay such as RNA sequencing for clarification.13 RNA-based NGS is therefore considered a gold standard for identifying NTRK gene fusions, as the intronic regions that cause technical issues in DNA-based NGS are not present.16,38 Given the diversity of fusion partners across tumor histologies, partner-agnostic fusion detection assays using RNA sequencing may represent the most optimal diagnostic approach for pan-cancer applications. One limitation to this analysis was the inconsistent level of reporting regarding testing methodology and testing practice in the literature. The level of detail reported on histology was also variable, precluding the ability to draw conclusions on trends with fusion partners. For many of the larger-scale studies, individual patient- or sample-level details were not consistently available, with some reporting only the NTRK gene or not reporting the specific tumor types associated with a given NTRK gene fusion. Many studies did not provide sample-level details on genomic profiling. Also, the functionality of the NTRK gene fusion transcript was not assessed or reported in many of these studies. Gene fusions that introduce a premature stop codon or other mechanisms that prevent the translation of the functional domains of the NTRK gene will not produce a functional fusion protein.39 Most studies did not provide breakpoint data or information on in-frame or tyrosine kinase domain status; thus, it was not possible to classify the fusions identified as pathogenic. It is also possible that there may be some overlap between the MSK and larotrectinib clinical trial databases. Because of the challenges of incomplete information in databases, efforts are currently ongoing to establish a systematic approach for categorizing NTRK gene fusions to expand on the knowledge in this area to help distinguish functional oncogenic fusions from structural variants of uncertain significance.40 A strength of this analysis is the further identification of NTRK gene fusion partners across tumors, which increases awareness of oncogenic fusion partners and informs the optimization of diagnostic tests. In addition, we have potentially identified tumor-specific fusion patterns. Furthermore, describing differences in fusion transcripts may highlight new and potentially actionable fusions for precision medicine indications, such as personalized vaccines and neoepitopes. The results of our analysis of the literature and genomic databases illustrate the diversity of NTRK gene fusion partners across various tumor types and expand the knowledge on the array of NTRK gene fusions observed in a wide range of solid tumors. This information highlights the importance of selecting the proper biomarker test to identify patients who may benefit from therapy with TRK inhibitors.